PREDICT vs CTS5 vs Oncotype Breast Prognosis Tools

2. PREDICT vs CTS5 vs Oncotype DX vs BCI

3. Practical Workflow Across the Breast Cancer Timeline

1. At initial post-operative planning: use clinicopathologic staging, receptor status, and tools such as PREDICT Breast to frame baseline prognosis and absolute systemic therapy benefit.
2. When chemotherapy benefit is uncertain in HR-positive/HER2-negative disease: consider genomic assays only if the patient matches the validated and guideline-supported population. Interpret the result with age, menopausal status, nodal status, and patient priorities.
3. During years 0-5 of endocrine therapy: focus on adherence, toxicity management, ovarian function suppression where indicated, bone health, and recurrence surveillance. Early prognostic tools should not be re-used as if they were dynamic recurrence monitors.
4. At the 5-year endocrine therapy decision point: use CTS5 to estimate residual late distant recurrence risk and consider BCI or other genomic information if available and appropriate.
5. Before changing treatment: document the exact clinical question, tool version, patient eligibility, and how the estimate influenced shared decision-making.

4. Tool-by-Tool Guidance

4.1 PREDICT Breast: survival and absolute treatment benefit

PREDICT is an online tool designed to help clinicians and patients see how treatments after surgery for early invasive breast cancer might improve survival. It is useful when a patient asks, "How much absolute benefit might chemotherapy, endocrine therapy, anti-HER2 therapy, bisphosphonates, or other adjuvant treatment add for someone like me?"

PREDICT is most helpful when used after primary surgery with complete pathology. It should be used cautiously, or not used, when the clinical scenario falls outside the model population, such as after neoadjuvant systemic therapy, in metastatic disease, or when pathology fields are uncertain.

Useful internal links: PREDICT Breast calculator and PREDICT Breast guide.

4.2 CTS5: residual late distant recurrence risk

CTS5 was developed as a simple clinicopathologic score for women with ER-positive primary breast cancer who completed 5 years of endocrine therapy and remained free of distant recurrence. It uses age, tumor size, grade, and nodal burden to categorize residual risk over years 5-10.

The key strength is practicality: the inputs are available from routine pathology and clinical records. The key limitation is equally important: CTS5 estimates risk, not endocrine therapy benefit. A high CTS5 score supports a more serious discussion about extended endocrine therapy, but the final decision should also consider prior toxicity, bone health, menopausal status, comorbidities, adherence, patient preference, and genomic information if available.

Useful internal links: CTS5 calculator and CTS5 guide.

4.3 Oncotype DX: genomic recurrence score and chemotherapy-benefit context

Oncotype DX reports a 21-gene Recurrence Score. The TAILORx trial clarified that many node-negative patients with intermediate scores do not benefit from chemotherapy, while younger patients at the higher end of the intermediate range may warrant more nuanced discussion. RxPONDER extended evidence to patients with 1-3 positive nodes and Recurrence Score 0-25, where menopausal status strongly affects interpretation.

Use Oncotype DX only in clinically eligible disease settings. It should not be used to de-escalate therapy in HER2-positive, triple-negative, inflammatory, metastatic, or high-nodal-burden scenarios outside its validated role.

Useful internal links: Oncotype DX calculator and Oncotype DX guide.

4.4 Breast Cancer Index: extended endocrine therapy context

Breast Cancer Index is a genomic assay used in selected HR-positive early breast cancer scenarios to inform late recurrence and extended endocrine therapy benefit discussions. It is not a general substitute for Oncotype DX, and it is not needed for every patient at year 5. It is most useful when the extended endocrine therapy decision remains uncertain after clinicopathologic review and when the assay is available within local practice.

Useful internal link: Breast Cancer Index tool.

5. Common Pitfalls

6. Frequently Asked Questions